Gefitinib.

Area of Science:

• Pharmacology and Medicinal Chemistry
• Oncology
• Drug Metabolism

Background:

• Gefitinib (Iressa®) is a targeted therapy inhibiting epidermal growth factor receptor (EGFR).
• It is clinically utilized for non-small cell lung cancer (NSCLC) resistant to chemotherapy.
• EGFR signaling is crucial for cell proliferation, survival, and blood vessel formation.

Purpose of the Study:

• To review synthesis pathways for Gefitinib.
• To summarize analytical techniques for Gefitinib determination.
• To provide an overview of Gefitinib's pharmacokinetic and safety profile.

Main Methods:

• Literature review of Gefitinib synthesis and analysis.
• Analysis of pharmacokinetic data including absorption, metabolism, and elimination.
• Compilation of reported adverse effects from clinical use.

Main Results:

• Multiple Gefitinib synthesis routes are available.
• Spectroscopic data (UV, IR) and analytical methods for Gefitinib are described.
• Gefitinib exhibits ~60% oral bioavailability, extensive hepatic metabolism (CYP3A4, CYP3A5, CYP2D6), and a plasma clearance of 595mL/min.
• Common adverse effects include diarrhea, rash, and nausea, generally mild and manageable.

Conclusions:

• Gefitinib is a key therapeutic agent for specific NSCLC populations.
• Understanding its synthesis, analysis, and pharmacokinetics is vital for effective clinical application.
• Adverse effects are typically manageable, supporting its continued use in targeted cancer therapy.